TINEA
MCID: DRM011
MIFTS: 52

Dermatophytosis (TINEA)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 74 15 71 32
Tinea 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD9CM 34 110
NCIt 49 C26745
SNOMED-CT 67 47382004
ICD10 32 B35 B35.9
UMLS 71 C0011636 C0040247

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea manuum and tinea unguium, and has symptoms including fever, pruritus and exanthema. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Ketoconazole and Luliconazole have been mentioned in the context of this disorder. Affiliated tissues include scalp, glabrous skin and nail, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 74 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 tinea manuum 33.8 CBSL B4GALNT2
2 tinea unguium 33.3 SQLE FLNA CBSL B4GALNT2
3 tinea profunda 33.1 CLEC7A CLEC6A CLEC4E CARD9
4 tinea corporis 32.6 SQLE FLNA DEFB4A CLEC6A CLEC4E CBSL
5 tinea capitis 32.6 SQLE SLC7A1 FLNC CLEC6A CBSL CARD9
6 tinea cruris 32.5 SQLE FLNA DEFB4A CYP51A1 CLEC6A CBSL
7 tinea pedis 32.0 SQLE HECTD4 DEFB4A CYP51A1 CLEC7A CLEC6A
8 superficial mycosis 31.5 POLR2B CLEC7A CLEC6A CLEC4E CBSL B4GALNT2
9 dermatomycosis 31.4 POLR2B CYP51A1 CLEC7A CD4 CBSL B4GALNT2
10 folliculitis 31.0 DEFB4A CD4 CCR6
11 fungal keratitis 30.6 CLEC7A CLEC4E
12 pityriasis versicolor 30.4 SQLE CLEC7A CLEC6A CLEC4E CBSL
13 aspergillosis 30.4 CSF1 CLEC7A CCR6
14 keratoconjunctivitis sicca 30.3 LTF CD4 CCR6
15 keratitis, hereditary 30.3 IL17A CD4 CCR6
16 scabies 30.2 FLNA CD4 CCR6
17 candidiasis 30.1 IL17A DEFB4A CYP51A1 CLEC7A CCR6 CARD9
18 seborrheic dermatitis 30.1 DEFB4A CLEC4E CD4 CCR6
19 nocardiosis 30.0 IL12RB1 CD4
20 cellulitis 30.0 IL17A DEFB4A CD4 CCR6
21 langerhans cell histiocytosis 30.0 IL17A CSF1 CCR6
22 t cell deficiency 29.9 IL17A CD4 CCR6
23 allergic contact dermatitis 29.9 IL17A DEFB4A CD4
24 chromoblastomycosis 29.8 CLEC7A CLEC6A CLEC4E CCR6 CBSL CARD9
25 bacterial infectious disease 29.8 LTF IL17A DEFB4A CD4 CCR6
26 cutaneous candidiasis 29.6 IL17A CLEC7A CLEC6A CCR6 CARD9 B4GALNT2
27 pneumocystosis 29.5 FLNC CLEC7A CLEC4E CD4 CCR6 CARD9
28 dermatitis, atopic 29.4 IL17A IL12RB1 DEFB4A CD4 CCR6
29 leprosy 3 29.3 IL17A HECTD4 FLNA CD4 CCR6
30 oral candidiasis 29.1 LTF IL17A DEFB4A CLEC7A CLEC6A CD4
31 chronic mucocutaneous candidiasis 28.7 IL17A IL12RB1 CSF1 CLEC7A CLEC6A CLEC4E
32 nail disease 28.5 IL17A IL12RB1 CLEC7A CLEC6A CLEC4E CD4
33 fungal infectious disease 28.2 IL17A IL12RB1 FLNC CYP51A1 CLEC7A CLEC6A
34 deep dermatophytosis 12.7
35 tinea barbae 12.0
36 candidiasis, familial, 2 11.6
37 tinea imbricata 10.9
38 tinea favosa 10.8
39 alopecia 10.6
40 skin disease 10.5
41 haemophilus influenzae 10.5 LTF CLEC7A
42 neonatal candidiasis 10.5 CLEC7A CLEC6A
43 inflammatory bowel disease 1 10.4 DEFB4A CCR6 CARD9
44 panophthalmitis 10.4 CD4 B4GALNT2
45 proctitis 10.4 LTF CSF1 CCR6
46 keratosis 10.4
47 vaginitis 10.4 DEFB4A CD4 CCR6
48 allergic hypersensitivity disease 10.3
49 dermatitis 10.3
50 blepharitis 10.3 LTF CD4 CCR6

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Dermatophytosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCR6 CLEC7A CSF1 CYP51A1 FLNA FLNC

MGI Mouse Phenotypes related to Dermatophytosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 B4GALNT2 CARD9 CBSL CCR6 CD4 CLEC4E
2 homeostasis/metabolism MP:0005376 10 B4GALNT2 CARD9 CBSL CCR6 CD4 CLEC4E
3 immune system MP:0005387 9.83 B4GALNT2 CARD9 CBSL CCR6 CD4 CLEC4E
4 respiratory system MP:0005388 9.17 CBSL CLEC7A CSF1 FLNA FLNC IL17A

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
2
Luliconazole Approved Phase 4 187164-19-8
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
5
Efinaconazole Approved Phase 4 164650-44-6
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
9
Zinc oxide Approved Phase 4 1314-13-2
10 Benzethonium Approved Phase 4 10172-60-8
11
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
12
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
13
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15 Hormones Phase 4
16 Hormone Antagonists Phase 4
17 Gastrointestinal Agents Phase 4
18 Cytochrome P-450 CYP3A Inhibitors Phase 4
19 Antacids Phase 4
20 Anti-Ulcer Agents Phase 4
21 Proton Pump Inhibitors Phase 4
22 Selenium disulfide Phase 4
23
Hydroxyitraconazole Phase 4
24 Anti-Infective Agents, Local Phase 4
25 Pharmaceutical Solutions Phase 4
26 Chlorhexidine gluconate Phase 4
27 Benzalkonium Compounds Phase 4
28 Antifungal Agents Phase 4
29 Anti-Infective Agents Phase 4
30
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
31
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
32
Griseofulvin Approved, Investigational, Vet_approved Phase 3 126-07-8 441140
33
Econazole Approved Phase 3 27220-47-9 3198
34
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
35
Naftifine Approved Phase 3 65472-88-0 47641 73342
36
Tavaborole Approved, Investigational Phase 3 174671-46-6
37
Amorolfine Approved, Investigational Phase 3 78613-35-1
38
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
39 Papaya Approved Phase 2, Phase 3
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
41
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
42
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
43 Trace Elements Phase 2, Phase 3
44 Micronutrients Phase 2, Phase 3
45 Anthelmintics Phase 2, Phase 3
46 Antiparasitic Agents Phase 2, Phase 3
47 Antiprotozoal Agents Phase 2, Phase 3
48 Tubulin Modulators Phase 2, Phase 3
49 Antimitotic Agents Phase 2, Phase 3
50 Respiratory System Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
2 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
3 An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Completed NCT02394340 Phase 4 Omeprazole 40 mg;Luliconazole Cream 1%
4 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
5 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
6 A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
7 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
8 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
9 An Open-Label, Proof of Concept Study to Determine the Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis Completed NCT00824863 Phase 4 ketoconazole 2% foam
10 The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial Completed NCT04007237 Phase 4 shampoo with different composition
11 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
12 Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study Recruiting NCT03923010 Phase 4 Itraconazole
13 A Study of Efficacy of Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination of Chlorhexidine Scrub and ZnO Nanoparticles Socks for Prevention of Pitted Keratolysis Not yet recruiting NCT04337749 Phase 4 Chorhexidine scrub
14 A Study of Efficacy of Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination of Chlorhexidine Scrub and ZnO Nanoparticles Socks for Treatment of Pitted Keratolysis Not yet recruiting NCT04332796 Phase 4 Chorhexidine scrub
15 Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses Terminated NCT01646580 Phase 4 ciclopirox
16 Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
17 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
18 Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis Unknown status NCT03320486 Phase 3 Dapaconazole;Ketoconazole
19 An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris Completed NCT01349998 Phase 3 Product 33525
20 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
21 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
22 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
23 Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
24 Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
25 An Open Label, Multicenter Trial Of Diflucan (Fluconazole) For 6 Weeks Given Once Daily To Pediatric Patients With Tinea Capitis Completed NCT00645242 Phase 3 fluconazole
26 A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
27 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
28 Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
29 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
30 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
31 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
32 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
33 A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
34 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
35 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
36 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
37 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
38 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
39 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
40 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
41 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
42 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
43 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
44 Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. Recruiting NCT02582177 Phase 3 Candicort®;Nizoral®;Baycuten N®;Canesten®
45 A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis. Recruiting NCT04203342 Phase 3 Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.);Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA);Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
46 A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis Terminated NCT01110330 Phase 3 Placebo cream;Ketoconazole 2% cream (formulation F012) (Nizoral);Ketoconazole 2% cream (formulation F126)
47 Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Withdrawn NCT02606383 Phase 3 Dapaconazole;Ketoconazole
48 A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Unknown status NCT03471455 Phase 2 Isotretinoin;Terbinafine;Itraconazole 200 mg
49 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
50 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

19
Scalp, Glabrous Skin, Nail

MalaCards organs/tissues related to Dermatophytosis:

40
Skin, Testes, Thyroid, T Cells, Brain, Colon, Thymus

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 6271)
# Title Authors PMID Year
1
First report of kerion (tinea capitis) caused by combined Trichophyton mentagrophytes and Microsporum canis. 61
32477858 2020
2
Congenital ichthyosis associated with Trichophyton rubrum tinea, imitating drug hypersensitivity reaction. 61
32547912 2020
3
β-Glucan augments IL-1β production by activating the JAK2/STAT3 pathway in cultured rabbit keratinocytes. 61
32224209 2020
4
Alarming India-wide phenomenon of antifungal resistance in dermatophytes: A multicentre study. 61
32301159 2020
5
Network pharmacology approach to elucidate possible action mechanisms of Sinomenii Caulis for treating osteoporosis. 61
32325182 2020
6
Scalp microbiota in members of a Japanese high school judo team including Trichophyton tonsurans carriers. 61
32548954 2020
7
Occurrence of Trichophyton verrucosum in cattle in the Ningxia Hui autonomous region, China. 61
32522200 2020
8
In vitro antidermatophytic synergism of double and triple combination of clioquinol with ciclopirox and terbinafine. 61
32506716 2020
9
One vs two negative fungal cultures to confirm mycological cure in shelter cats treated for Microsporum canis dermatophytosis: a retrospective study. 61
31268401 2020
10
Periocular Tinea Faciei. 61
32171560 2020
11
Visual Dermatology: Tinea Faciei Incognito With Invasion of Vellus Hair. 61
32564620 2020
12
Tinea incognito infection with Trichophyton erinacei from a pet hedgehog. 61
32538462 2020
13
A prickly souvenir from a hedgehog café: tinea manuum secondary to Trichophyton erinacei via international spread. 61
31580504 2020
14
Visual Dermatology: Tinea Capitis: Fluorescence Under Wood's Light. 61
32573255 2020
15
Successful photodynamic therapy of tinea capitis child with liver dysfunction caused by oral antifungal drugs: A case report. 61
32198021 2020
16
Current burden of serious fungal infections in Republic of Congo. 61
32181941 2020
17
Dermatoscopy of tinea corporis. 61
32034804 2020
18
Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. 61
32538466 2020
19
Atypical extensive tinea corporis caused by Trichophyton tonsurans. 61
32497801 2020
20
Nannizzia incurvata as a rare cause of favus and tinea corporis in Cambodia and Vietnam. 61
32525102 2020
21
Varicella and herpes zoster appearing over sites of tinea corporis, hitherto unreported examples of immunocompromised districts: a case series. 61
32072634 2020
22
Epidemiological survey of 42 403 dermatophytosis cases examined at Nagasaki University Hospital from 1966 to 2015. 61
32293052 2020
23
Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis. 61
32139093 2020
24
Erratum to "Comparison of in vitro antifungal activity of novel triazoles with old antifungal agents against dermatophyte species caused tinea pedis" [J. Mycol. Med. 30 (2020) 100935]. 61
32534827 2020
25
Caution and warning: Arrival of terbinafine-resistant Trichophyton interdigitale of the Indian genotype, isolated from extensive dermatophytosis, in Japan. 61
32157721 2020
26
Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro characterization and clinical assessment of an analogous loaded carbopol gel. 61
32266837 2020
27
Pseudomycetoma of the scalp caused by Microsporum canis. 61
32278631 2020
28
Tinea capitis: dermoscopy and calcium fluorescent microscopy as highly efficient and precise diagnostic tools. 61
32276798 2020
29
Tinea Capitis: Bedside Diagnosis by Dermoscopy. 61
32386873 2020
30
Adult Tinea capitis in China: A retrospective analysis from 2000 to 2019. 61
32395886 2020
31
Treatment Adherence and Psychosocial Impact of Tinea Capitis in Families - qualitative pilot study. 61
32406149 2020
32
Impact on quality of life in patients with dermatophytosis. 61
31691274 2020
33
Magnitude, characteristics and consequences of topical steroid misuse in rural North India: an observational study among dermatology outpatients. 61
32430446 2020
34
[Microsporum ferrugineum-an anthropophilic dermatophyte in Germany : Case report and review of the literature]. 61
32394081 2020
35
Tinea barbae due to Trichophyton rubrum successfully treated using oral fosravuconazole l-lysine ethanolate. 61
32372437 2020
36
Trichophyton indotineae sp. nov.: A New Highly Terbinafine-Resistant Anthropophilic Dermatophyte Species. 61
32449054 2020
37
A prospective study on patterns of topical steroids self-use in dermatophytoses and determinants predictive of cutaneous side effects. 61
32449316 2020
38
Molecular epidemiology of Tinea gladiatorum in contact sports in northern Iran. 61
32096252 2020
39
Species distribution of the main aetiologic agents causing skin dermatophytosis in Colombian patients: A 23-year experience at a Mycological Reference Center. 61
32163641 2020
40
Invitro Activity of Four Commonly Available Antifungal Drugs against Dermatophytes Species Isolated From Clinical Samples Using Disk Diffusion Method in Mymensingh. 61
32506099 2020
41
Mo-CBP4, a purified chitin-binding protein from Moringa oleifera seeds, is a potent antidermatophytic protein: In vitro mechanisms of action, in vivo effect against infection, and clinical application as a hydrogel for skin infection. 61
32004601 2020
42
Trichophyton species and Microsporum gypseum infection and fomite carriage in cats from three animal shelters: a retrospective case series. 61
31070544 2020
43
Internal Transcribed Spacer rDNA and TEF-1α Gene Sequencing of Pathogenic Dermatophyte Species and Differentiation of Closely Related Species Using PCR-RFLP of The Topoisomerase II. 61
31606971 2020
44
Evaluation of an Explanted Porcine Skin Model to Investigate Infection with the Dermatophyte Trichophyton rubrum. 61
32108288 2020
45
Luliconazole, a highly effective imidazole, against Fusarium species complexes. 61
32253502 2020
46
Clinical isolates of Trichophyton rubrum are completely inhibited by photochemical treatment with a γ-cyclodextrin formulation of curcuminoids. 61
31975440 2020
47
A review of the traditional use of southern African medicinal plants for the treatment of fungal skin infections. 61
31899200 2020
48
Efficacy of Itraconazole in the Prevention of Recurrence of Tinea Versicolor: A Three Year Follow Up. 61
32506089 2020
49
The effect of cytoplasmic crude extracts of Trichophyton verrucosum on cell mediated immunity. 61
32334947 2020
50
Identification and Testing of Antidermatophytic Oxaborole-6-Benzene Sulphonamide Derivative (OXBS) from Streptomyces atrovirens KM192347 Isolated from Soil. 61
32294942 2020

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.85 CSF1 CLEC7A CLEC6A CLEC4E CARD9
2 cytokine-mediated signaling pathway GO:0019221 9.73 IL17A IL12RB1 CSF1 CD4
3 immune response GO:0006955 9.65 IL17A DEFB4A CLEC4E CD4 CCR6
4 defense response to Gram-negative bacterium GO:0050829 9.54 LTF DEFB4A CD4
5 immune system process GO:0002376 9.5 LTF CSF1 CLEC7A CLEC6A CLEC4E CD4
6 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.4 CLEC7A CD4
7 positive regulation of monocyte differentiation GO:0045657 9.32 CSF1 CD4
8 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.16 IL17A CLEC7A
9 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.02 LTF FLNA CLEC6A CD4 CARD9

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pattern recognition receptor activity GO:0038187 8.62 CLEC7A CLEC4E

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....